Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nomacopan Phase IIa in Bullous Pemphigoid
NCT04035733Phase 2Completed
- Sponsor
- Akari Therapeutics
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in Bullous Pemphigoid (BP), sponsored by Akari Therapeutics. Primary endpoint: Safety parameter at 42 days. Started Sep 2018; status: completed.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04035733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035733.